NCT00723359View on ClinicalTrials.gov

Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

April 30, 2012

Study Completion Date

April 30, 2012

Conditions
Multiple Myeloma
Interventions
DRUG

BT062

biologic

Trial Locations (4)

10029

Mount Sinai Medical Center, New York

14263

Roswell Park Cancer Institute, Buffalo

30322

Emory University Winship Cancer Institute, Atlanta

02115

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

Biotest
All Listed Sponsors
collaborator

Biotest

INDUSTRY

lead

Biotest Pharmaceuticals Corporation

INDUSTRY

NCT00723359 - Safety and Dose Determining Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter